Skip to main content
Sirio Pharma Co., Ltd. logo

Sirio Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 300791 ISIN · CNE100003NB0 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,174 across all filing types
Latest filing 2026-02-04 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300791

About Sirio Pharma Co., Ltd.

https://www.siriopharma.com

Sirio Pharma Co., Ltd. is a global contract development and manufacturing organization (CDMO) specializing in dietary supplements and nutraceuticals. The company provides comprehensive services encompassing product formulation, manufacturing, and packaging. Its portfolio includes diverse delivery formats such as softgels, gummies, tablets, hard capsules, powders, and oral liquids. Sirio Pharma emphasizes innovation in delivery systems, offering specialized solutions like plant-based softgels and advanced probiotic formulations. The organization adheres to rigorous quality management systems and maintains multiple international certifications to meet global regulatory standards. Serving an international clientele, the company supports health and wellness brands through scalable production capacities and integrated supply chain solutions.

Recent filings

Filing Released Lang Actions
关于第三届职工代表大会第七次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolution passed at the third session of the employee representative meeting of Xianle Health Technology Co., Ltd. It discusses the approval of the 2026 employee stock ownership plan draft and states that the plan will be submitted to the shareholders' meeting for approval. The document is short (859 characters) and serves as a formal announcement of a meeting decision rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is not a full report but an announcement of a meeting resolution. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-02-04 Chinese
关于向香港联交所递交境外上市股份（H股）发行上市申请并刊发申请资料的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the submission of an application for overseas listing of H shares on the Hong Kong Stock Exchange. It includes links to the application materials but does not contain the actual application or financial data. The document explicitly states it is an announcement to inform investors and that the listing is subject to regulatory approvals. The document length is short (1062 characters), and it serves as a notice rather than a full report or detailed filing. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-01-30 Chinese
东方财富证券股份有限公司关于仙乐健康科技股份有限公司2023年限制性股票激励计划（草案二次修订稿）之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report issued by 东方财富证券股份有限公司 regarding the 2023 Restricted Stock Incentive Plan of 仙乐健康科技股份有限公司. It contains detailed analysis, definitions, statements, assumptions, approval procedures, revisions to the incentive plan, and the advisor's verification opinions. The content focuses on the stock incentive plan, its approval, and financial advisory opinions rather than financial statements or earnings results. It is not an annual or interim financial report, earnings release, or regulatory filing. It is a standalone advisory report related to a capital incentive plan, which fits best under the category of Capital/Financing Update (CAP) because it deals with stock incentives and related capital matters. The document length is substantial and contains detailed advisory content, not just an announcement or certification, so it is not RPA or RNS.
2026-01-29 Chinese
2025年限制性股票激励计划（草案修订稿）
Remuneration Information Classification · 95% confidence The document is titled "仙乐健康科技股份有限公司 2025 年限制性股票激励计划（草案修订稿）" which translates to "Xianle Health Technology Co., Ltd. 2025 Restricted Stock Incentive Plan (Draft Revision)". It extensively details a stock incentive plan involving restricted stock awards to management and key employees, including the number of shares, vesting schedules, eligibility criteria, legal compliance, and governance structure. The document references relevant laws and regulations such as the Company Law, Securities Law, and stock exchange rules. It is a comprehensive plan document outlining the terms and conditions of a stock-based incentive program rather than an announcement or a brief summary. It is not a financial report, earnings release, or a regulatory filing announcement. It is also not a proxy solicitation or voting results announcement. The content fits the category of Remuneration Information (DEF 14A) filings, which cover executive and director compensation plans, including stock incentive plans. Therefore, the appropriate classification is DEF 14A with high confidence.
2026-01-29 Chinese
2025年限制性股票激励计划实施考核管理办法（修订稿）
Governance Information Classification · 95% confidence The document is titled as an implementation and assessment management method for a 2025 restricted stock incentive plan by the company. It details the performance assessment criteria, procedures, and management related to the stock incentive plan. It is a policy or governance document related to the company's stock incentive plan and internal governance mechanisms. It does not contain financial statements, earnings data, or regulatory filings of financial results. It is not an announcement of a report but a detailed internal governance document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices, including incentive plans and related management rules.
2026-01-29 Chinese
2023年限制性股票激励计划（草案二次修订稿）
Remuneration Information Classification · 95% confidence The document is titled "仙乐健康科技股份有限公司 2023 年限制性股票激励计划（草案二次修订稿）" which translates to "Xianle Health Technology Co., Ltd. 2023 Restricted Stock Incentive Plan (Draft Second Revision)". The content extensively details a stock incentive plan including the number of shares, eligibility, grant price, vesting conditions, performance targets, legal compliance, and governance related to the stock incentive plan. It is a comprehensive plan document outlining the terms and conditions of a restricted stock incentive program for company executives and key employees. This type of document is related to executive compensation and stock-based remuneration. According to the filing definitions, a report detailing compensation for top executives and directors falls under "Remuneration Information (DEF 14A)". The document is not an announcement or a brief summary but a detailed plan, so it is not a Regulatory Filing or Report Publication Announcement. Therefore, the correct classification is "DEF 14A" with high confidence.
2026-01-29 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.